Insulet Corp. logo
PODDInsulet Corp.

Average Debt/Equity Ratio

Debt/Equity Ratio

The latest reported debt/equity ratio is 0.73 as of Tuesday, March 31, 2026, shown against its trailing averages.

PODD Debt/Equity Ratio

PODD Average Debt/Equity Ratio

PODD Debt/Equity Ratio Averages

DEBT/EQUITY RATIO LATEST REPORTED

0.73

DEBT/EQUITY RATIO TTM

0.88

DEBT/EQUITY RATIO 3Y

1.51

DEBT/EQUITY RATIO 5Y

1.99

DEBT/EQUITY RATIO 10Y

2.60

DEBT/EQUITY RATIO 15Y

2.38

DEBT/EQUITY RATIO 20Y

2.11

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy